China Medicine Corporation, primarily a manufacturer, distributor and developer of Western pharmaceuticals, traditional Chinese medicines, and other nutraceuticals, has appointed Fred Wai-Kuen Cheung as its chief financial officer.
Cheung brings over 18 years of professional expertise in auditing, financial and general management through his experience working with a "Big Four" auditing firm, a multi-national corporation, a private equity fund, and public and private companies based in Asia. Prior to joining China Medicine, Cheung was an investment manager at CLSA Capital Partners (HK) Ltd. Previously, Cheung was the financial controller for Podium Development Co., Ltd. in Hong Kong and China. Cheung also worked at VTech Holdings Limited for more than four years, holding various senior positions. Cheung was the accounting manager for DuPont China Ltd., stationed in Shenzhen, PRC for over three years. Cheung began his career at Deloitte Touche Tohmatsu focusing on auditing for over three years. Cheung has a bachelor's degree in Accountancy from Hong Kong Polytechnic University. Cheung received his CPA from the Hong Kong Institute of Certified Public Accountants in January 1997 and ACCA from the Association of Chartered Certified Accountants in April 1995.